REVIEW

Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs [version 1; peer review: 2 approved]

Tomas Koltai

Centro de Diagnóstico y Tratamiento de la Obra Social del Personal de la Industria de la Alimentación, Talar, Buenos Aires, C1122AAL, Argentina

V1 First published: 22 Jul 2015, 4:297
<https://doi.org/10.12688/f1000research.6789.1>
Latest published: 22 Jul 2015, 4:297
<https://doi.org/10.12688/f1000research.6789.1>

Abstract

Objective: To determine the exact role of sodium channel proteins in migration, invasion and metastasis and understand the possible anti-invasion and anti-metastatic activity of repurposed drugs with voltage gated sodium channel blocking properties.

Material and methods: A review of the published medical literature was performed searching for pharmaceuticals used in daily practice, with inhibitory activity on voltage gated sodium channels. For every drug found, the literature was reviewed in order to define if it may act against cancer cells as an anti-invasion and anti-metastatic agent and if it was tested with this purpose in the experimental and clinical settings.

Results: The following pharmaceuticals that fulfill the above mentioned effects, were found: phenytoin, carbamazepine, valproate, lamotrigine, ranolazine, resveratrol, ropivacaine, lidocaine, mexiletine, flunarizine, and riluzole. Each of them are independently described and analyzed.

Conclusions: The above mentioned pharmaceuticals have shown anti-metastatic and anti-invasion activity and many of them deserve to be tested in well-planned clinical trials as adjunct therapies for solid tumors and as anti-metastatic agents. Antiepileptic drugs like phenytoin, carbamazepine and valproate and the vasodilator flunarizine emerged as particularly useful for anti-metastatic purposes.

Keywords

Voltage-gated sodium channels, cancer, phenytoin, flunarizine, repurposed drugs, metastasis

Open Peer Review

Approval Status

	1	2
version 1
22 Jul 2015	view	view

1. **Stephen G. Waxman**, Yale University, New Haven, USA
2. **Michihiro Mutoh**, National Cancer Center, Chuo-ku, Japan

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Tomas Koltai (tkoltai@hotmail.com)

Competing interests: The authors declared no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2015 Koltai T. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Koltai T. **Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs [version 1; peer review: 2 approved]** F1000Research 2015, 4:297 <https://doi.org/10.12688/f1000research.6789.1>

First published: 22 Jul 2015, 4:297 <https://doi.org/10.12688/f1000research.6789.1>

Introduction

The capacity to metastasize is one of the hallmarks of cancer¹ and usually death due to cancer is not caused by the primary tumor but rather by the metastatic spread². The lack of an effective therapy in prevention of metastasis results in a high mortality rate in oncology. So it seems reasonable that if the risk of metastasis can be reduced, the outlook of cancer patients may significantly improve survival and quality of life. Solving the metastasis problem is solving the cancer problem³.

Many natural products, like genistein⁴, resveratrol⁵ and curcumin^{6,7} have shown interesting anti-metastasis activity. The same effect has been observed with older pharmaceuticals like aspirin⁸, not-as-old pharmaceuticals such as celecoxib^{6,9}; new pharmaceuticals like ticagrelor¹⁰, as well as with more sophisticated molecules like dasatinib and ponatinib⁶ or ultrasophisticated drugs, like polymeric plerixafor¹¹.

Many other compounds have also been identified as possessing anti-metastatic effects, including increases in NO¹², cimetidine, doxycycline, heparin and low molecular heparins, and metapristone¹³.

High creativity has been employed in the search for anti-metastatic compounds. For example, Ardiani *et al.* developed a vaccine-based immunotherapy to enhance CD4 and CD8 T lymphocyte activity against Twist¹⁴. Twist is a transcription factor involved in invasion and metastasis.

Many known pharmaceuticals that are, or were, in use for other purposes than cancer treatment are demonstrating anti-metastatic activity. This is the case for thiobendazole, which is an antifungal, anti-parasitic drug that has been used in medical practice for over 40 years, but which also shows anti-migratory and apoptosis-inducing activity¹⁵. The introduction of Food and Drug Administration (FDA)-approved products which are used for a purpose

different for which it was originally approved is called repurposing of a drug.

Many new drugs are being introduced in the area of anti-metastatic activity. One such example, zoledronic acid¹⁶ is a biphosphonate that decreases bone metastasis. Denosumab¹⁷ is another example. It is a monoclonal antibody directed against the receptor activator of nuclear factor kappa B ligand (RANKL) that diminishes the number of circulating cancer cells and prevents bone metastasis. It is in Phase II clinical trials and has the advantage of subcutaneous administration, while zoledronic acid requires intravenous route (for further information on these compounds, see clinical trials NCT01952054, NCT01951586, NCT02129699)¹⁸.

Metastasis is a multi-step development. The different steps in the metastatic cascade can be targeted with a combination of drugs against each step. Migration and invasion are necessary steps for the metastatic cascade. There is no metastasis without prior migration of malignant cells, so that if migration and invasion are blocked, metastasis should not occur.

Invasion is the first step in metastasis, and in a very simplified view, it can be divided into three stages (Shown schematically in Figure 1):

1. Translocation of cells across extracellular matrix barriers
2. Degradation of matrix proteins by specific proteases
3. Cell migration

Voltage-gated sodium channels

Neurons and muscle cells (and excitable tissues in general) express voltage-gated sodium channel (VGSC) proteins; tumor cells may also express these proteins. VGSCs are important players in migration and invasion as it will be described in this manuscript.

Figure 1. Repurposed drugs acting at different levels of the metastatic cascade. (uPA: urinary plasminogen activator).

Sodium channels were first described by Hodgkin and Huxley in 1952 and knowledge about structure and physiology of VGSCs are mainly the result of seminal investigations developed by William Catterall¹⁹.

Sodium channels are glycosylated transmembrane proteins that form passages in the cell membrane for the penetration of sodium into the intracellular space according to their electrical gradients. Voltage-gated sodium channels (also known as VGSCs or 'NaV' channels) refers to the mechanism that triggers these proteins to allow sodium movement across the membrane.

There are nine known VGSCs (Nav1.1 to Nav1.9) that are members of the superfamily of VGSCs. Nav1.1, 1.2, 1.3 and 1.6 are found in the central nervous system. Nav1.4 is found in muscle and Nav1.5 in cardiac muscle²⁰.

VGSC is formed by a large subunit (α) and other smaller subunits (β). The α subunit is the core of the channel and is fully functional by itself, even without the presence of β subunits^{19–21}.

When a cell expresses VGSC α subunits, this means that it is capable of conducting sodium into the cell. The structure of VGSC can be seen in [Figure 2](#) and [Figure 3](#). VGSCs modulate the exchange of Na⁺ across the cell membrane and the inflow of this electrolyte spikes the action potential in excitable tissues²².

It is well known that expression of VGSCs appears in cancer cells where it is not expressed in their normal counterparts, and plays a significant role in disease progression. [Table 1](#) shows examples of the cancer tissues in which dysregulated expression of VGSCs were identified and the role they play.

Figure 2. An idealized drawing of α and β units of VGSCs.

Figure 3. Surface and side view of VGSC.

Table 1. VGSC functional over-expression in different cancer tissues.

Cancer	Reference	Findings
Human breast cancer	Fraser, 2005 ²³	VGSC (neonatal isoform of NaV1.5) was significantly upregulated in metastatic cells. VGSC activity increased endocytosis, migration and invasion
Non small-cell lung cancer (NSCLC)	Roger, 2007 ²⁴	Strongly metastatic cell lines have functional VGSCs while normal cells do not have it. Inhibition of channels with tetrodotoxin (TTX) reduced invasiveness by 50%.
Small cell lung cancer (SCLC)	Blandino, 1995 ²⁵	VGSCs are over-expressed in SCLC.
Cervical cancer cells	Diaz, 2007 ²⁶	Na _v 1.2, Na _v 1.4, Na _v 1.6, and Na _v 1.7 transcripts were detected in cervical cancer cell specimens.
Prostate cancer	Bennett, 2004 ²⁷	VGSC expression increases with invasion capacity that can be blocked with TTX. Increased VGSC expression is enough to increase invasive phenotype.
Metastatic ovarian cancer cells	Gao, 2010 ²⁸	Highly metastatic ovarian cells showed significantly elevated expression of Nav1.2, Nav1.4, Nav1.5 and Nav1.7. TTX reduced migration and invasion around 50%.
Human colon cancer cells	House, 2010 ²⁹	SCN5A, the gene coding for α subunit of VGSC is a regulator of the invasive phenotype.
T lymphocytes (Jurkat cells)	Fraser, 2004 ³⁰	Jurkat cells express VGSC and this protein has an important role in invasiveness of these cells.
Pancreatic cancer cells	Sato K, 1994 ³¹	MIA-PaCa-2 and CAV cells were tested <i>in vitro</i> and <i>in vivo</i> with phenytoin (PHEN). Both cell lines showed growth inhibition in a dose dependable manner. This might be due to VGSC overexpression according to our criteria (the authors think that this was due to calcium channel blocking).
Mesothelial neoplastic cells	Fulgenzi, 2006 ³²	Express VGSCs, particularly NaV1.2, and NaV1.6, and NaV1.7. TTX decreased cell motility and migration.

Targeting these channels may represent a legitimate way of reducing or blocking the metastatic process.

The role of sodium channel in invasion, metastasis and carcinogenesis is insufficiently known.

Sodium channel proteins and cancer

In 1995, Grimes *et al.*³³ investigated the differential electrophysiological characteristics of VGSCs in two different rodent prostate cancer cell lines: the Mat-Ly-Lu cell line, which is a highly metastatic line (more than 90% of metastasis to lung and lymph nodes under experimental conditions) and the AT-2 cell line with a much lower metastatic potential (less than 10% chance of developing metastasis in experimental conditions). They found fundamental differences in electrophysiological features between these two cell lines which displayed a direct relationship with *in vitro* invasiveness. Sodium inward currents were detected only in the Mat-Ly-Lu cell line and inhibition of VGSC protein with Tetrodotoxin (TTX; a powerful inhibitor of VGSCs) significantly reduced the capacity for invasion (mean reduction 33%). On the other hand, TTX showed no effect on invasion of AT-2 cell lines. The TTX-induced reduction of invasion showed a direct correlation with the amount of cells expressing VGSC in the culture.

No fundamental differences in the potassium channels were found between the two cell lines, except for a lower density of potassium channels in the Mat-Ly-Lu cell line. The authors concluded that ion channels may be involved in malignant cell behavior and that VGSCs could play a role in the metastatic process.

In 1997, Laniado *et al.*³⁴ investigated the presence of VGSC in human prostate cell lines. As in the Grimes research they used two different cell lines: one with a low metastatic potential: the LN-Cap cell line which is androgen dependent and expresses prostate-specific antigen, and the PC-3 line which is more malignant, does not express prostate-specific antigen and exhibits a high rate of metastatic potential.

As in the work by Grimes *et al.*, they found that PC-3, the more malignant cell line, expressed VGSC protein and that inhibition of this channel protein with TTX reduced invasion in a significant way. LN-Cap cells did not express VGSC.

One of the conclusions reached by the authors was that cancer cells expressing functional VGSC had a selective advantage regarding migration and distant metastasis. In the case of both humans and rodents, not all cells in the highly malignant cell cultures showed

the presence of the VGSC protein. For example, in PC-3 cell culture only 10% of cells expressed a functional VGSC protein. This is the reason why the authors consider these cells as a clonal evolution that gives pro-tumor and pro-invasive advantages.

The correlation between VGSC protein expression and invasiveness in human and rat prostate cancer cells was confirmed by Smith *et al.*³⁵ by comparing seven lines of rat prostate carcinoma cells with different metastatic ability, and nine human prostate carcinoma cell lines. In general, invading capacity of the basement membrane and metastatic ability showed a positive correlation with the percentage of cells expressing VGSC. But this positive correlation between percentage of cells expressing VGSCs and the percentage of cells being invasive occurred only up to 27% of the cells being invasive in the rat series and up to 12% of cells being invasive in the human series. Authors suggested that these discrepancies may be due to the necessity of other factors for invasive capability besides VGSC presence; i.e. this protein may represent a prerequisite for the invasive phenotype but other requirements must also be achieved for a full-blown invasive phenotype. Fraser *et al.*³⁶ determined the key role played by VGSCs in prostate cancer cells in invasion and motility and showed that TTX and phenytoin (PHEN) that are known VGSC blockers, decreased motility and invasiveness while channel openers increased motility. However, the increased invasion capacity in VGSC-expressing cancer cells is not limited to prostate cancers.

The same features were found in breast cancer cell lines MCF-7 (estrogen receptor positive), MDA-MB-231 and MDA-MB-468 (both estrogen receptor negative).

Baciotglu *et al.*³⁸ when experimenting on a rat model of induced breast cancer showed the importance of inhibiting VGSCs in order to inhibit antioxidant response. They observed a survival improvement in rats treated with a VGSC blocker.

An important location of VGSCs in cancer cells is in a cellular region directly involved in migration and invasion: the invadopodia. Invadopodia are protrusions of the plasma membrane, rich in actin that are strongly related to degradation of the extracellular matrix (ECM). Figure 4 and Figure 5 summarize how invadopodia works and the relation between VGSC and invadopodia.

According to Brisson *et al.*³⁹, NaV 1.5 Na⁺ channels regulate the NHE-1 exchanger protein that increases proton extrusion with extracellular matrix acidification that promotes invasion and migration through activity of cysteine cathepsins and degradation of extracellular matrix⁴⁰.

A second mechanism of invasion promotion was described by Mader *et al.*⁴¹ through the EGFR-Src-cortactin pathway. Src is activated by VGSCs and Src phosphorylates cortactin. Cortactin is

Figure 4. Proton extrusion through VGSC and NHE-1 (sodium hydrogen exchanger-1) produces acidification of extracellular matrix surrounding the cellular membrane (yellow area in the figure). (Brisson 2013³⁹; Gillet 2009⁴⁰). Acidification activates cathepsine degradation of the extracellular matrix.

Figure 5. VGSCs. The second mechanism of action is through activation of Src which increases MMP-2 and MMP-9 secretion and activity through phosphorylation of Cortactin. It is postulated that there is a feedback loop starting with MMPs products which induces the development of new invadopodia (Red circle around I). (This figure has been constructed based on references Gillet 2009⁴⁰, Brissin 2013¹³³, Clark 2007⁴² and Mader 2011⁴¹).

involved in MMP-9 and MMP-2 upregulation and secretion as can be seen in Figure 5. These events lead to matrix degradation, an integral step in cancer cell invasion⁴².

There are nine different VGSC α subunits and four different β subunits. The expression of these subunits may vary in the different tumor cells²¹. For example, NaV 1.5 is overexpressed in astrocytoma, breast and colon cancer. NaV 1.7 is found in breast, prostate and non small-cell lung cancer (NSCLC) and NaV 1.6 in cervical and prostate cancer. This suggests that the α subunits seem to be tissue specific.

The main players in the invadopodia complex, besides the VGSCs are Src kinase, cortactin and Rho-A GTPase. The exact relation between these players is not fully known and needs further research. (For further reading on invadopodia and cortactin, see references 43,44).

One possible relation between invadopodia-Src-VGSCs is described in Figure 6.

Onganer and Djamgoz⁴⁵ proposed the hypothesis that VGSC upregulation enhances the metastatic phenotype by enhancing endocytic membrane activity in SCLC.

Andrikopoulos *et al.*⁵⁰ have demonstrated that VGSCs have pro-angiogenic functions by significantly increasing vascular

endothelial growth factor (VEGF) signaling in endothelial cells. Endothelial cells express NaV1.5 and NaV1.7. TTX blocks, and NaV1.5 RNAi decreases endothelial cell proliferation and tubular differentiation that are essential steps in the angiogenesis process.

The important implications of VGSCs in cancer progression and invasion led Litan and Langhans⁵¹ to express that cancer is a channelopathy (For further reading on structure and functions of VGSC see reference 52).

Material and methods

A search was performed in the medical literature to find pharmaceuticals already in use for other purposes than cancer, that as an off-target effect could inhibit VGSCs and to determine if these pharmaceuticals can actually decrease migration, invasion and metastatic potential of cancer. A Pubmed advanced search retrieved 50519 articles under the search condition "voltage-gated sodium channel blocker" during the period of 1981–2015.

The articles that considered drugs that were not in clinical use or FDA-approved were not included in this study, with the exception of resveratrol and natural polyphenols.

The following drugs fulfilling these criteria were found: phenytoin, carbamazepine, lamotrigine valproate, ranolazine, resveratrol, ropivacaine, lidocaine, mexiletine, flunarizine, and riluzole.

Figure 6. Tarone *et al.*⁴⁶ in 1985 reported the relation between the oncogenic Src and promotion of invadopodia. Berdeaux *et al.*⁴⁷ reported that the small molecule GTPase Rho A activity is under control of oncogenic Src and localizes in the invadopodia complex and Dulong *et al.*⁴⁸ (2013) showed that Rho-A regulates the expression and activity of NaV1.5 and found a positive feedback between NaV1.5 and Rho A in breast cancer cells. According to Timpson *et al.*⁴⁹, cooperation between mutant p53 and oncogenic Ras activates Rho-A.

Figure 7. Activities of alpha and beta-1 subunits of VGSCs in cancer^{131–133}.

A new search was performed in Pubmed for each of the above listed pharmaceuticals with two search criteria: 1) the drug and 2) the term cancer. The period considered was from 1962 to the current time.

Those VGSC blocking drugs that exhibited anti-cancer activity based mainly by other mechanisms are only briefly mentioned; valproic acid and lamotrigine probably act against cancer by histone deacetylase inhibition and riluzole's anti-cancer mechanism is probably related to the glutamatergic pathway.

Tetrodotoxin is also analyzed in spite of the fact that it is not in clinical use, because it is the traditional model molecule of VGSC blocking, against which other drugs are comparatively tested in the experimental setting.

Results

Tetrodotoxin (TTX)

Many biological toxins like those found in scorpions and sea anemones develop their toxicity by introducing modifications to the

properties of VGSCs⁵². This toxicity can be achieved by inactivation of VGSCs (as in the case of TTX) or on the contrary by persistent activation of the channel (in the case of veratridine, acinitine and many others).

TTX is a powerful biological neurotoxin found in fishes of the Tetraodontiformes order and certain symbiotic bacteria. TTX binds to VGSCs and blocks its activity, mainly in the nervous system. It is used as a biotoxin for defensive or predatory purposes. TTX binds to the extracellular portion of VGSC, disabling the function of the ion channel and results in a very poisonous effect producing death through respiratory paralysis²².

Due to its high toxicity it is not used as a therapeutic agent, but TTX has been very useful in the experimental setting for the study of VGSCs physiology.

Phenytoin (Diphenylhydantoin; PHEN)

PHEN is an anticonvulsant that has been identified as a sodium channel blocker^{53,54} which has been held responsible for inducing lymphoma, pseudolymphoma, hematological malignancies and other cancers in patients under chronic treatment⁵⁵. This carcinogenic effect of phenytoin was not confirmed in large epidemiological studies⁵⁶. PHEN diminishes cell mediated immunity⁵⁷.

Vernillo *et al.* in 1990⁵⁸ found that phenytoin inhibited bone resorption in rat osteosarcoma cells through significant reduction of collagenase and gelatinase activities. But Dyce *et al.*⁵⁹ did not find evidence of PHEN's gelatinase inhibitory activity in B16 melanoma cells *in vitro*. This may be evidence of tissue-specific activity which has not been investigated any further. Dyce *et al.* did not find

important anti-metastatic activity either in a melanoma tail injection model in mice. But when the data of this publication is examined in detail, it seems that the anti-metastatic activity is not so low as mentioned by the authors: they found that after injection of tumor cells in the mice protected with PHEN, the animal developed mean pulmonary colonies 4.6 +/- 3.1 but when the mice received no PHEN, developed. 10.2 +/- 9.9 colonies. Beyond any statistical analysis the difference seems important.

Yang *et al.*⁶⁰ found that NaV 1.5 was over-expressed in breast cancer cells with high metastatic potential, and the anticonvulsant PHEN had the ability to reduce migration and invasion at clinically achievable concentrations in MDA-MB-231 cells (which are strongly metastatic) and showed no effects on MCF-7 cells with low metastatic potential.

PHEN blocks Na⁺ channels and has a high affinity for VGSCs in the inactivated state of the channel⁶¹. Compared with verapamil, lidocaine and carbamazepine, PHEN had an intermediate potency between verapamil and lidocaine, being verapamil the strongest inhibitor and carbamazepine the weakest.

Abdul *et al.*⁶² studied the effect of four anticonvulsants (PHEN, carbamazepine, valproate and ethosuxinide) on the secretion of prostate specific antigen and interleukin-6 in different human prostate cancer cell lines. PHEN and carbamazepine inhibited the secretion of both.

Fadiel *et al.*⁶³ found that PHEN is a strong estrogen receptor α antagonist at clinically achievable concentrations and at the same time is a weak agonist.

Table 2. Summary of PHEN's activity against cancer and metastasis.

Reference	Findings
Nelson, 2015 ⁶⁴	PHEN at clinically achievable concentration reduces breast cancer growth, invasion and metastasis <i>in vivo</i> in a xenograft model.
Yang M, 2012 ⁶⁰	At clinically achievable concentration PHEN inhibited migration and invasion of highly metastatic breast cancer MDA-MB-231 cell line, and had no effect on MCF-7 cell line which has a low metastatic potential and do not express VGSCs.
Lee Ts, 2010 ⁶⁵	DPTH-N10 a phenytoin derivate drug, inhibits proliferation of COLO 205 colon cancer cell line.
Lyu Y, 2008 ⁶⁶	DPTH-N10 a phenytoin derivate drug, shows strong anti-angiogenic activity. Inhibits HUVEC proliferation and capillary like tube formation.
Sikes, 2003 ⁶⁷	New VGSC blockers based on PHEN, showed increased inhibition of prostate cancer growth.
Anderson, 2003 ⁶⁸	Developed new VGSC blockers based on the PHEN binding site study. These new VGSC blockers showed potent inhibition of prostate cancer cells growth (Androgen independent PC3 line).
Fraser, 2003 ³⁶	PHEN decreased motility of prostate cancer cells.
Abdul, 2001 ⁶²	PHEN and carbamazepine decreased PSA secretion in human prostate carcinoma cell lines.
Lobert, 1999 ⁶⁹	PHEN has inhibitory effects on microtubule assembly and has additive effects with vinblastine.
Kawamura, 1996 ⁷⁰	PHEN potentiates vinblastine citotoxicity.
Sato K, 1994 ³¹	PHEN decreased growth of MIA PaCa-2 (pancreatic cancer cells).
Lang DG, 1993 ⁷¹	PHEN, Carbamazepine and lamotrigine are inhibitors of sodium channels and reduces glutamate release in rat neuroblastoma cells.
Tittle, 1992 ⁷²	PHEN decreased growth in six murine tumor cell lines of lymphoid origin.

There is an undesired side effect of PHEN that may represent a drawback for its use in cancer: immunological depression^{73–76}. This is an issue that deserves further research. Finally it has to be mentioned that PHEN interacts with many other pharmaceuticals, particularly those usually employed in chemotherapy.

In summary, the main activities developed by PHEN in relation with cancer are:

VGSC blocking, microtubule polymerization blocking, immunosuppression, calcium channel blocking and enhancement of vinblastine cytotoxicity.

Carbamazepine

Carbamazepine is a sodium channel blocker, pro-autophagy agent and histone deacetylase inhibitor that has been in use since 1962 for the treatment of seizures, neuropathic pain and bipolar disorders and has shown interesting anti-metastatic potential in the experimental setting⁷⁷. Studies have also insinuated preventative effects in prostate cancer⁷⁸.

Carbamazepine induces Her2 protein degradation through the proteasome without modifying its production⁷⁹. This activity seems to be related to histone deacetylase inhibition rather than VGSC blocking. Growth inhibition in estrogen-receptor positive breast cancer cell lines seems probably a histone deacetylase inhibitor effect⁸⁰.

Oxcarbazepine, a molecule related to carbamazepine is also a sodium channel blocker⁸¹ and a potassium channel blocker, but it has not been investigated for cancer.

The anti-cancer mechanisms shown by carbamazepine are in summary:

- 1) VGSC blocker as anti-metastatic⁷⁷.
- 2) Histone deacetylase inhibition⁸².
- 3) Her2 degradation by proteasome⁷⁹.

Valproic acid (VAL)

An anticonvulsant drug that exerts multiple actions related to anti-cancer effects: calcium channel blocker, VGSC blocker, inhibition of histone deacetylase, potentiation of inhibitory activity of GABA, decreases angiogenesis, interferes with MAP kinase pathways and the β catenin-Wnt pathway⁸³. Val is being tested in various clinical trials in leukemias and solid tumors⁸⁴. Most of the anti-tumor activities of VAL seem to be related to the inhibition of histone deacetylase rather than VGSC blocking and further discussion goes beyond the scope of this review.

Ranolazine

Ranolazine, (Ranexa) is an antiarrhythmic drug indicated for the treatment of chronic angina that was first approved by FDA in 2006. Common side effects are dizziness, constipation, headache and nausea⁸⁵.

Ranolazine inhibits the late inward sodium current in heart muscle, so that it works as a sodium channel inhibitor. Ranolazine is metabolized by the CYP3A enzyme.

Drifford *et al.*⁸⁶ demonstrated that ranolazine inhibition of NaV1.5 reduced breast cancer cells invasiveness *in vivo* and *in vitro* using the highly invasive MDA-MB-231 breast cancer cell line. This drug also efficiently decreased the activity of the embryonic/neonatal isoform of NaV1.5 (the active isoform usually found in human breast cancer cells). Ranolazine did not change the viability of the cell. It also decreased the pro-invasive morphology of MDA-MB-231 breast cancer cells. They also demonstrated that injection of cancer cells through the tail vein of nude mice at non-toxic doses achieved a significant reduction in metastatic colonization.

Resveratrol and other polyphenols

Certain biologically active natural phenols like resveratrol and genistein have shown effects on VGSCs, increasing hyperpolarized potentials during steady state inactivation⁸⁸.

Resveratrol's inhibitory effects on VGSC has consequences for the behaviour of metastatic cells. Fraser *et al.*⁸⁹ showed that resveratrol significantly decreased lateral and transversal motility and invasion capacity of rat prostate cancer cells (MAT-Ly-Lu cells), without changes in cellular viability. They also found that resveratrol inhibited VGSC in a dose-dependent manner and using TTX with resveratrol did not increase VGSC inhibition nor metastatic cell behavior. Resveratrol also inhibits epithelial sodium channels⁹⁰.

Resveratrol is not the only polyphenol with VGSC blocking activity: quercetin and catechin showed similar effects⁹¹ in ventricular myocytes and genistein in rat cervical ganglia⁹² and nociceptive neurons⁹³.

Gabapentin

Gabapentin is used for the treatment of pain and decreases expression of NaV1.7 and ERK-1/ERK-2 in ganglion neurons^{94,95} and expression of NaV1.2⁹⁶. We found no publications about gabapentin as a possible anti-metastasis or anti-invasion treatment.

Riluzole

Riluzole is a drug used for amyotrophic lateral sclerosis and it is a known sodium channel blocker. This effect was demonstrated in human prostate cancer cell lines⁹⁷. Most likely, the anticancer activity of riluzole is mainly related to other anticancer characteristics of this drug like downregulation of the glutamatergic pathway⁹⁸.

Flunarizine

Flunarizine is a calcium channel blocker with a long plasma half-life, used in migraine prevention, vertigo and adjuvant treatment of epilepsy, but has shown important activity as a VGSC blocker^{99–101}. It binds calmodulin.

At low temperatures (22 degrees) flunarizine potentiates the binding of phenytoin to VGSC¹⁰².

Flunarizine has shown anti-cancer activities in lymphoma and multiple myeloma¹⁰³, and leukaemia¹⁰⁴, but these anti-cancer activities were apparently related to induction of apoptosis, which is not a consequence of VGSC blockage. On melanoma cells, flunarizine showed decreased motility and invasion *in vitro*^{105,106}. Flunarizine inhibited migration and phagocytosis in B16 melanoma cells and M5076 macrophage-like cancer cells¹⁰⁷.

According to data found in medical literature we may consider anti-cancer activities of flunarizine in the following way:

- a) Activities dependent on VGSC blocking: decreased motility and invasion^{105–107}.
- b) Activities dependent on calcium channel blocking: vasodilatation and increased concentration of chemotherapeutic drugs in tumor tissues^{108–110}, and increased radiosensitivity due to better oxygen delivery to anoxic areas of the tumor¹¹¹.
- c) WNT inhibition¹⁰³.
- d) Inhibition of lymphangiogenesis¹¹².
- e) Increase of melphalan's cytotoxicity in resistant ovarian cancer cells¹¹³ and in rhabdomyosarcoma¹¹⁴.
- f) Positive modulation of doxorubicin in multidrug resistant phenotype colon adenocarcinoma cells¹¹⁵.
- g) Decreased blood viscosity improving oxygen delivery to the tumor¹¹⁶.
- h) Other anti-tumor activities: apoptosis and growth rate inhibition^{103,104,117}.

Flunarizine has not been tested in cancer trials. The fact that it can significantly reduce motility in melanoma cells which is a highly metastasizing tumor and is also an inhibitor of lymphangiogenesis, makes it an interesting adjuvant therapy that deserves further research. The possible synergy with phenytoin is also an issue that should be explored.

However, flunarizine has also shown cytoprotective effects in certain tissues (auditory cells) against cisplatin¹¹⁸ and flunarizine may induce Nrf-2 overexpression that confers resistance to chemotherapy in some tumors like Her2 positive breast cancer¹¹⁹.

Local anaesthetics

Local anaesthetics eliminate pain through VGSC blocking on nociceptive neurones.

Local anaesthetics like lidocaine have shown interesting anti-cancer effects in various cancer cells. Lidocaine is a VGSC blocker. The mechanisms involved in decreased proliferation seems related to the inhibitory actions of local anaesthetics on EGFR¹²⁰ rather than VGSC blocking. Inhibition of invasion found in cancer cells treated

with lidocaine (HT1080, HOS, and RPMI-7951) by Mammoto *et al.* was attributed by the authors to shedding of the extracellular domain of heparin binding epidermal growth factor-like growth factor and not to VGSC blocking¹²¹.

Baptista-Hon *et al.* described a decrease in metastatic potential of colon cancer cells (SW620 cells) by ropivacaine and decrease of Nav1.5 function (adult and neonatal isoforms)¹²².

Piegeler *et al.*, 2012 identified decreased Src activity produced by amide-linked anaesthetics as an independent mechanism of migration and invasion decrease¹²³.

Other drugs

Other drugs that have shown significant VGSC blocking activity and may have activity in the fight against migration, invasion and metastasis are: fluoxetine blocks Nav1.5¹²⁴, and mexiletine¹²⁵.

Intravenous propofol has been recognized as an anti-invasion drug in HeLa, HT1080, HOS and RPMI-75 cells by decreasing actin stress-fiber formation and focal adhesion inhibition, but this drug is not a VGSC blocker and the probable mechanism is through Rho-A modulation¹²⁶.

All of the drugs we have mentioned are low cost pharmaceuticals, have predictable and well known side effects, and therefore they are adequate candidates for further clinical trials.

Discussion

Functionally active VGSCs are expressed in many metastatic cancer cells. This functional expression is an integral element of the metastatic process in many different solid tumors.

The essential role of this protein in invadopodia has been established, so VGSCs became a legitimate target to decrease migration, invasion and metastasis. Repurposed drugs like anticonvulsants, (phenytoin in particular) have shown interesting anti-invasion effects.

Carbamazepine's ability to induce Her2 protein degradation should be considered an interesting association to trastuzumab.

Targeting VGSCs may act in synergy with anti-angiogenic treatments and with other chemotherapeutic drugs like vinblastine.

On the other hand in the review by Besson *et al.*¹²⁷ there is a very important remark: VGSC is also present in macrophages and cells related with the immunologic system, so that disrupting VGSC's activity may deteriorate also anti-tumor immunologic mechanisms.

Flunarizine represents a particularly interesting molecule because it may attack cancer from four different angles: invasion and migration through VGSC blocking, WNT pathway down-regulation, decreased lymphangiogenesis and better oxygenation of hypoxic areas which permits a better arrival of chemotherapeutic drugs and increased sensitivity to radiation. It has never been tested in clinical trials for cancer treatment.

Future directions

New VGSCs blockers are under research. Sikes *et al.*⁶⁷ developed new blockers based on the phenytoin binding site to VGSC. They found compounds with enhanced activity in VGSC blocking and antitumor activity against human prostate cancer cells.

The association of two or more VGSC blockers may show synergistic enhanced anti-metastatic activity. Nerve growth factor (NGF) increases the number of VGSCs¹²⁹; tanezumab, a new NGF inhibitor diminishes the amount of VGSCs¹²⁸, so we may assume that tanezumab may develop synergistic activity with VGSC blockers. Tanezumab has not been tested in cancer and we think it deserves more research because NGF is also an anti-apoptotic protein¹³⁰.

Stettner *et al.*¹³⁴ found that men over 50 years of age may be benefited with the use of anticonvulsants, regarding prostate cancer prevention because they observed lower PSA levels compared with control

groups. They also described a ranking of this preventive activity: valproic acid>levetiracetam>carbamazepine/oxcarbazepine>lamotrigine. The authors also observed synergy between these drugs.

Conclusions

Repurposed VGSC blocker drugs, particularly phenytoin, flunarizine and polyphenols, deserve clinical trials as complementary treatment to decrease the metastatic risk.

Competing interests

The authors declared no competing interests.

Grant information

The author(s) declared that no funds were involved in supporting this work.

References

- Hanahan D, Weinberg RA: **Hallmarks of cancer: the next generation.** *Cell.* 2011; **144**(5): 646–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Mehlen P, Puisieux A: **Metastasis: a question of life or death.** *Nat Rev Cancer.* 2006; **6**(6): 449–458.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Taketo MM: **Reflections on the spread of metastasis to cancer prevention.** *Cancer Prev Res (Phila).* 2011; **4**(3): 324–328.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pavese JM, Krishna SN, Bergan RC: **Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis.** *Am J Clin Nutr.* 2014; **100**(Suppl 1): 431S–436S.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Yang X, Li X, Ren J: **From French Paradox to cancer treatment: anti-cancer activities and mechanisms of resveratrol.** *Anticancer Agents Med Chem.* 2014; **14**(6): 806–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Xiong A, Yang Z, Shen Y, *et al.*: **Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.** *Cancers (Basel).* 2014; **6**(2): 926–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kronski E, Fiori ME, Barbieri O, *et al.*: **miR181b is induced by the chemopreventive polyphenol curcumin and inhibits breast cancer metastasis via down-regulation of the inflammatory cytokines CXCL1 and -2.** *Mol Oncol.* 2014; **8**(3): 581–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Langley RE, Rothwell PM: **Aspirin in gastrointestinal oncology: new data on an old friend.** *Curr Opin Oncol.* 2014; **26**(4): 441–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Li WW, Long GX, Liu DB, *et al.*: **Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity.** *Pharmazie.* 2014; **69**(2): 132–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gebremeskel S, LeVatte T, Liwski RS, *et al.*: **The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer.** *Int J Cancer.* 2015; **136**(1): 234–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Li J, Oupický D: **Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor.** *Biomaterials.* 2014; **35**(21): 5572–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lu Y, Yu T, Liang H, *et al.*: **Nitric oxide inhibits hetero-adhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initiating metastatic cascade.** *Sci Rep.* 2014; **4**: 4344.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wang J, Chen J, Wan L, *et al.*: **Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486).** *AAPS J.* 2014; **16**(2): 289–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ardiani A, Gameiro SR, Palena C, *et al.*: **Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.** *Cancer Res.* 2014; **74**(7): 1945–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Zhang J, Zhao C, Gao Y, *et al.*: **Thiabendazole, a well-known antifungal drug, exhibits anti-metastatic melanoma B16F10 activity via inhibiting VEGF expression and inducing apoptosis.** *Pharmazie.* 2013; **68**(12): 962–8.
[PubMed Abstract](#)
- Rietkötter E, Menck K, Bleckmann A, *et al.*: **Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion.** *Oncotarget.* 2013; **4**(9): 1449–60.
[PubMed Abstract](#) | [Free Full Text](#)
- Rolfo C, Raez LE, Russo A, *et al.*: **Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.** *Expert Opin Biol Ther.* 2014; **14**(1): 15–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
- NCT01952054, NCT01951586, NCT02129699.
[Reference Source](#)
- Catterall WA: **Voltage-gated sodium channels at 60: structure, function and pathophysiology.** *J Physiol.* 2012; **590**(Pt 11): 2577–2589.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Termin A, Martinborough E, Wilson D: **Chapter 3 – Recent Advances in Voltage-Gated Sodium Channel Blockers: Therapeutic Potential as Drug Targets in the CNS.** *Annu Rep Med Chem.* 2008; **43**: 43–60.
[Publisher Full Text](#)
- Brackenbury WJ: **Voltage-gated sodium channels and metastatic disease.** *Channels (Austin).* 2012; **6**(5): 352–361.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lee CH, Ruben PC: **Interaction between voltage-gated sodium channels and the neurotoxin, tetrodotoxin.** *Channels (Austin).* 2008; **2**(6): 407–412.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fraser SP, Diss JK, Chioni AM, *et al.*: **Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis.** *Clin Cancer Res.* 2005; **11**(15): 5381–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Roger S, Rollin J, Barascu A: **Voltage-gated sodium channels potentiate the invasive capacities of human non-small-cell lung cancer cell lines.** *Int J Biochem Cell Biol.* 2007; **39**(4): 774–786.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Blandino JK, Viglione MP, Bradley WA, *et al.*: **Voltage-dependent sodium channels in human small-cell lung cancer cells: role in action potentials and inhibition by Lambert-Eaton syndrome IgG.** *J Membr Biol.* 1995; **143**(2): 153–163.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Diaz D, Delgadillo DM, Hernández-Gallegos E, *et al.*: **Functional expression of voltage-gated sodium channels in primary cultures of human cervical cancer.**

- J Cell Physiol.* 2007; **210**(2): 469–478.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Bennett ES, Smith BA, Harper JM: **Voltage-gated Na⁺ channels confer invasive properties on human prostate cancer cells.** *PLoS Arch.* 2004; **44**(6): 908–914.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Gao R, Shen Y, Cai J, *et al.*: **Expression of voltage-gated sodium channel alpha subunit in human ovarian cancer.** *Oncol Rep.* 2010; **23**(5): 1293–1299.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. House CD, Vaske CJ, Schwartz AM, *et al.*: **Voltage-gated Na⁺ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion.** *Cancer Res.* 2010; **70**(17): 6957–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 30. Fraser SP, Diss JK, Lloyd LJ, *et al.*: **T-lymphocyte invasiveness: control by voltage-gated Na⁺ channel activity.** *FEBS Lett.* 2004; **569**(1-3): 191–194.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Sato K, Ishizuka J, Cooper CW, *et al.*: **Inhibitory effect of calcium channel blockers on growth of pancreatic cancer cells.** *Pancreas.* 1994; **9**(2): 193–202.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Fulgenzi G, Graciotti L, Faronato M, *et al.*: **Human neoplastic mesothelial cells express voltage-gated sodium channels involved in cell motility.** *Int J Biochem Cell Biol.* 2006; **38**(7): 1146–1159.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Grimes JA, Fraser SP, Stephens GJ, *et al.*: **Differential expression of voltage-activated Na⁺ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro.** *FEBS Lett.* 1995; **369**(2-3): 290–294.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Laniado ME, Lalani EN, Fraser SP: **Expression and functional analysis of Voltage-activated Na⁺ channels in human prostate cancer cell lines and their contribution to invasion in vitro.** *Am J Pathol.* 1997; **150**(4): 1213–1221.
[PubMed Abstract](#) | [Free Full Text](#)
 35. Smith P, Rhodes NP, Shortland AP, *et al.*: **Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells.** *FEBS Lett.* 1998; **423**(1): 19–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Fraser SP, Salvador V, Manning EA, *et al.*: **Contribution of functional voltage-gated Na⁺ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. Lateral motility.** *J Cell Physiol.* 2003; **195**(3): 479–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Roger S, Besson P, Le Guennec JY: **Involvement of a novel fast inward sodium current in the invasion capacity of a breast cancer cell line.** *Biochim Biophys Acta.* 2003; **1616**(2): 107–111.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Batcioglu K, Uyumlu AB, Satilmis B, *et al.*: **Oxidative stress in the in vivo DMBA rat model of breast cancer: suppression by a voltage-gated sodium channel inhibitor (RS100642).** *Basic Clin Pharmacol Toxicol.* 2012; **111**(2): 137–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Brisson L, Driffort V, Benoist L, *et al.*: **Na_v1.5 Na⁺ channels allosterically regulate the NHE-1 exchanger and promote the activity of breast cancer cell invadopodia.** *J Cell Sci.* 2013; **126**(Pt 21): 4835–4842.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Gillet L, Roger S, Besson P, *et al.*: **Voltage-gated Sodium Channel Activity Promotes Cysteine Cathepsin-dependent Invasiveness and Colony Growth of Human Cancer Cells.** *J Biol Chem.* 2009; **284**(13): 8680–8691.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Mader CC, Oser M, Magalhaes MA, *et al.*: **An EGFR-Src-Arg-Cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion.** *Cancer Res.* 2011; **71**(5): 1730–1741.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. Clark ES, Whigham AS, Yarbrough WG, *et al.*: **Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia.** *Cancer Res.* 2007; **67**(9): 4227–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Murphy DA, Courtneidge MA: **The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function.** *Nat Rev Mol Cell Biol.* 2011; **12**(7): 413–426.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 44. Cosen-Binker LI, Kapus A: **Cortactin: the gray eminence of the cytoskeleton.** *Physiology (Bethesda).* 2006; **21**: 352–361.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Onganer PU, Djamgoz MB: **Small-cell lung cancer (human): potentiation of endocytic membrane activity by voltage-gated Na⁺ channel expression in vitro.** *J Membr Biol.* 2005; **204**(2): 67–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Tarone G, Cirillo D, Giancotti FG, *et al.*: **Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes.** *Exp Cell Res.* 1985; **159**(1): 141–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Berdeaux RL, Diaz B, Kim L, *et al.*: **Active Rho is localized to podosomes induced by oncogenic Src and is required for their assembly and function.** *J Cell Biol.* 2004; **166**(3): 317–323.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Dulong C, Fang YJ, Gest C, *et al.*: **The small GTPase RhoA regulates the expression and function of the sodium channel Nav1.5 in breast cancer cells.** *Int J Oncol.* 2014; **44**(2): 539–547.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Timpson P, McGhee EJ, Morton JP, *et al.*: **Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53.** *Cancer Res.* 2011; **71**(3): 747–757.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Andrikopoulos P, Fraser SP, Patterson L, *et al.*: **Angiogenic functions of voltage-gated Na⁺ Channels in human endothelial cells: modulation of vascular endothelial growth factor (VEGF) signaling.** *J Biol Chem.* 2011; **286**(19): 16846–16860.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Litan A, Langhans SA: **Cancer as a channelopathy: ion channels and pumps in tumor development and progression.** *Front Cell Neurosci.* 2015; **9**: 86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 52. Denac H, Mevissen M, Scholtysik G, *et al.*: **Structure, function and pharmacology of voltage-gated sodium channels.** *Naunyn Schmiedeberg Arch Pharmacol.* 2000; **362**(6): 453–479.
[PubMed Abstract](#)
 53. Matsuki N, Quandt FN, Ten Eick RE, *et al.*: **Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells.** *J Pharmacol Exp Ther.* 1984; **228**(2): 523–30.
[PubMed Abstract](#)
 54. Willow M, Gonoi T, Catterall WA, *et al.*: **Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells.** *Mol Pharmacol.* 1985; **27**(5): 549–58.
[PubMed Abstract](#)
 55. Schwinghammer TL, Howrie DL: **Phenytoin-induced lymphadenopathy.** *Drug Intell Clin Pharm.* 1983; **17**(6): 460–2.
[PubMed Abstract](#)
 56. Olsen JH, Boyce JD Jr, Jenssen JP, *et al.*: **Cancer among epileptic patients exposed to anticonvulsant drugs.** *J Natl Cancer Inst.* 1989; **81**(10): 803–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Okamoto Y, Shimizu K, Tamura K, *et al.*: **Effects of phenytoin on cell-mediated immunity.** *Cancer Immunol Immunother.* 1988; **26**(2): 176–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. Vernillo AT, Ramamurthy NS, Lee HM, *et al.*: **The effect of phenytoin on collagenase and gelatinase activities in UMR 106-01 rat osteoblastic osteosarcoma cells.** *Matrix.* 1990; **10**(1): 27–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. Dyce M, Sharif SF, Whalen GF, *et al.*: **Search for anti-metastatic therapy: effects of phenytoin on B16 melanoma metastasis.** *J Surg Oncol.* 1992; **49**(2): 107–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. Yang M, Kozminski DJ, Wold LA, *et al.*: **Therapeutic potential for phenytoin: targeting Na_v1.5 sodium channels to reduce migration and invasion in metastatic breast cancer.** *Breast Cancer Res Treat.* 2012; **134**(2): 603–615.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Ragsdale DS, Scheuer T, Catterall WA, *et al.*: **Frequency and voltage dependent inhibition of type IIA Na⁺ channels, expressed in a mammalian cell line by local anesthetic, antiarrhythmic and anticonvulsant drugs.** *Mol Pharmacol.* 1991; **40**(5): 756–765.
[PubMed Abstract](#)
 62. Abdul M, Hoosein N: **Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells.** *Anticancer Res.* 2001; **21**(3B): 2045–8.
[PubMed Abstract](#)
 63. Fadiel A, Song J, Tivon D, *et al.*: **Phenytoin is an estrogen receptor α -selective modulator that interacts with helix 12.** *Reprod Sci.* 2015; **22**(2): 146–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Nelson M, Yang M, Dowle AA, *et al.*: **The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis.** *Mol Cancer.* 2015; **14**(1): 13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. Lee TS, Chen LC, Liu Y, *et al.*: **5,5-Diphenyl-2-thiohydantoin-N10 (DPH-N10) suppresses proliferation of cultured colon cancer cell line COLO-205 by inhibiting DNA synthesis and activating apoptosis.** *Naunyn Schmiedeberg Arch Pharmacol.* 2010; **382**(1): 43–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Liu Y, Wu J, Ho PY, *et al.*: **Anti-angiogenic action of 5,5-diphenyl-2-thiohydantoin-N10 (DPH-N10).** *Cancer Lett.* 2008; **271**(2): 294–305.
[PubMed Abstract](#) | [Publisher Full Text](#)
 67. Sikes RA, Walls AM, Brennen WN, *et al.*: **Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers.** *Clin Prostate Cancer.* 2003; **2**(3): 181–187.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Anderson JD, Hansen TP, Lenkowski PW, *et al.*: **Voltage-gated sodium channel blockers as cytostatic inhibitors of the androgen-independent prostate cancer cell line PC-3.** *Mol Cancer Ther.* 2003; **2**(11): 1149–54.
[PubMed Abstract](#)
 69. Lobert S, Ingram JW, Correia JJ, *et al.*: **Additivity of dilantin and vinblastine inhibitory effects on microtubule assembly.** *Cancer Res.* 1999; **59**(19): 4816–22.
[PubMed Abstract](#)

70. Kawamura KI, Grabowski D, Weizer K, *et al.*: **Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells.** *Br J Cancer.* 1996; 73(2): 183–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Lang DG, Wang CM, Cooper BR: **Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells.** *J Pharmacol Exp Ther.* 1993; 266(2): 829–35.
[PubMed Abstract](#)
72. Tittle TV, Schaumann BA, Rainey JE, *et al.*: **Segregation of the growth slowing effects of valproic acid from phenytoin and carbamazepine on lymphoid tumor cells.** *Life Sci.* 1992; 50(14): PL79–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
73. Dosch HM, Jason J, Gelfand EW: **Transient antibody deficiency and abnormal t-suppressor cells induced by phenytoin.** *N Engl J Med.* 1982; 306(7): 406–409.
[PubMed Abstract](#) | [Publisher Full Text](#)
74. Sorrell TC, Forbes IJ: **Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro.** *Clin Exp Immunol.* 1975; 20(2): 273–85.
[PubMed Abstract](#) | [Free Full Text](#)
75. Fontana A, Grob PJ, Sauter R, *et al.*: **IgA deficiency, epilepsy, and hydantoin medication.** *Lancet.* 1976; 2(7979): 228–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Marcoli M, Gatti G, Ippoliti G, *et al.*: **Effect of chronic anticonvulsant monotherapy on lymphocyte subpopulations in adult epileptic patients.** *Hum Toxicol.* 1985; 4(2): 147–157.
[PubMed Abstract](#)
77. Teichmann M, Kretschy N, Kopf S, *et al.*: **Inhibition of tumour spheroid-induced prometastatic intravasation gates in the lymph endothelial cell barrier by carbamazepine: drug testing in a 3D model.** *Arch Toxicol.* 2014; 88(3): 691–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Stettner M, Krämer G, Strauss A, *et al.*: **Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer.** *Eur J Cancer Prev.* 2012; 21(1): 55–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Meng Q, Chen X, Sun L, *et al.*: **Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.** *Mol Cell Biochem.* 2011; 348(1–2): 165–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Meng QW, Zhao CH, Xi YH, *et al.*: **[Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells].** *Ai Zheng.* 2006; 25(8): 967–73.
[PubMed Abstract](#)
81. Huang CW, Huang CC, Lin MW, *et al.*: **The synergistic inhibitory actions of oxcarbazepine on voltage-gated sodium and potassium currents in differentiated NG108-15 neuronal cells and model neurons.** *Int J Neuropsychopharmacol.* 2008; 11(5): 597–610.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Beutler AS, Li SD, Nicol R, *et al.*: **Carbamazepine is an inhibitor of histone deacetylases.** *Life Sci.* 2005; 76(26): 3107–3115.
[PubMed Abstract](#) | [Publisher Full Text](#)
83. Kostrouchová M, Kostrouch Z, Kostrouchová M: **Valproic acid, a molecular lead to multiple regulatory pathways.** *Folia Biol (Praha).* 2007; 53(2): 37–49.
[PubMed Abstract](#)
84. Michaelis M, Doerr HW, Cinatl J Jr: **Valproic acid as anti-cancer drug.** *Curr Pharm Des.* 2007; 13(33): 3378–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Banon D, Filion KB, Budlovsky T, *et al.*: **The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.** *Am J Cardiol.* 2014; 113(6): 1075–1082.
[PubMed Abstract](#) | [Publisher Full Text](#)
86. Drifford V, Gillet L, Bon E, *et al.*: **Ranolazine inhibits Na_v1.5-mediated breast cancer cell invasiveness and lung colonization.** *Mol Cancer.* 2014; 13: 264.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Djamgoz MB, Onkal R: **Persistent current blockers of voltage-gated sodium channels: a clinical opportunity for controlling metastatic disease.** *Recent Pat Anticancer Drug Discov.* 2013; 8(1): 66–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
88. Ingolfsson HI, Thakur P, Herold KF, *et al.*: **Phytochemicals perturb membranes and promiscuously alter protein function.** *ACS Chem Biol.* 2014; 9(8): 1788–1798.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. Fraser SP, Peters A, Fleming-Jones S, *et al.*: **Resveratrol: inhibitory effects on metastatic cell behaviors and voltage-gated Na⁺ channel activity in rat prostate cancer in vitro.** *Nutr Cancer.* 2014; 66(6): 1047–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Weixel KM, Marciszyn A, Alzamora R, *et al.*: **Resveratrol inhibits the epithelial sodium channel via phosphoinositides and AMP-activated protein kinase in kidney collecting duct cells.** *Plos One.* 2013; 8(19): e78019.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. Wallace CH, Baczkó I, Jones L, *et al.*: **Inhibition of cardiac voltage-gated sodium channels by grape polyphenols.** *Br J Pharmacol.* 2006; 149(6): 657–665.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
92. Jia Z, Jia Y, Liu B, *et al.*: **Genistein inhibits voltage-gated sodium currents in SCG neurons through protein tyrosine kinase-dependent and kinase-independent mechanisms.** *Pflugers Arch.* 2008; 456(5): 857–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
93. Liu L, Yang T, Simon SA: **The protein tyrosine kinase inhibitor, genistein, decreases excitability of nociceptive neurons.** *Pain.* 2004; 112(1–2): 131–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Zhang JL, Yang JP, Zhang JR, *et al.*: **Gabapentin reduces allodynia and hyperalgesia in painful diabetic neuropathy rats by decreasing expression level of Nav1.7 and p-ERK1/2 in DRG neurons.** *Brain Res.* 2013; 1493: 13–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
95. Yang RH, Wang WT, Chen JY, *et al.*: **Gabapentin selectively reduces persistent sodium current in injured type-A dorsal root ganglion neurons.** *Pain.* 2009; 143(1–2): 48–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
96. Liu Y, Qin N, Reitz T, *et al.*: **Inhibition of the rat brain sodium channel Nav1.2 after prolonged exposure to gabapentin.** *Epilepsy Res.* 2006; 70(2–3): 263–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. Abdul M, Hoosein N: **Voltage-gated sodium ion channels in prostate cancer: expression and activity.** *Anticancer Res.* 2002; 22(3): 1727–30.
[PubMed Abstract](#)
98. Wall BA, Wangari-Talbot J, Shin SS, *et al.*: **Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.** *Pigment Cell Melanoma Res.* 2014; 27(2): 263–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
99. Kiskin NI, Chizhnikov IV, Tsyndrenko AY, *et al.*: **R56865 and flunarizine as Na⁺-channel blockers in isolated Purkinje neurons of rat cerebellum.** *Neuroscience.* 1993; 54(3): 575–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
100. Fischer W, Kittner H, Regenthal R, *et al.*: **Anticonvulsant profile of flunarizine and relation to Na⁺ channel blocking effects.** *Basic Clin Pharmacol Toxicol.* 2004; 94(2): 79–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
101. Ye Q, Yan LY, Xue LJ, *et al.*: **Flunarizine blocks voltage-gated Na⁺ and Ca²⁺ currents in cultured rat cortical neurons: A possible locus of action in the prevention of migraine.** *Neurosci Lett.* 2011; 487(3): 394–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
102. Francis J, Burnham WM: **[3H]Phenytoin identifies a novel anticonvulsant-binding domain on voltage-dependent sodium channels.** *Mol Pharmacol.* 1992; 42(6): 1097–103.
[PubMed Abstract](#)
103. Schmeel LC, Schmeel FC, Kim Y, *et al.*: **Flunarizine exhibits in vitro efficacy against lymphoma and multiple myeloma cells.** *Anticancer Res.* 2015; 35(3): 1369–76.
[PubMed Abstract](#)
104. Conrad DM, Furlong SJ, Doucette CD, *et al.*: **The Ca²⁺ channel blocker flunarizine induces caspase-10-dependent apoptosis in Jurkat T-leukemia cells.** *Apoptosis.* 2010; 15(5): 597–607.
[PubMed Abstract](#) | [Publisher Full Text](#)
105. Fink-Puches R, Helige C, Karl H, *et al.*: **Inhibition of melanoma cell directional migration in vitro via different cellular targets.** *Exp Dermatol.* 1993; 2(1): 17–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
106. Hofmann-Wellenhorst R, Fink-Puches R, Smolle J, *et al.*: **Correlation of melanoma cell motility and invasion in vitro.** *Melanoma Res.* 1995; 5(5): 311–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
107. Sezzi ML, De Luca G, Materazzi M, *et al.*: **Effects of a calcium-antagonist (flunarizine) on cancer cell movement and phagocytosis.** *Anticancer Res.* 1985; 5(3): 265–71.
[PubMed Abstract](#)
108. Kaelin WG Jr, Shrivastav S, Jirtle RL: **Blood flow to primary tumors and lymph node metastases in SMT-2A tumor-bearing rats following intravenous flunarizine.** *Cancer Res.* 1984; 44(3): 896–9.
[PubMed Abstract](#)
109. Bellelli A, Camboni C, de Luca G, *et al.*: **In vitro and in vivo enhancement of vincristine antitumor activity on B16 melanoma cells by calcium antagonist flunarizine.** *Oncology.* 1987; 44(1): 17–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
110. Vaupel P, Menke H: **Blood flow, vascular resistance and oxygen availability in malignant tumours upon intravenous flunarizine.** *Adv Exp Med Biol.* 1987; 215: 393–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
111. Wood PJ, Hirst DG: **Cinnarizine and flunarizine as radiation sensitizers in two murine tumours.** *Br J Cancer.* 1988; 58(6): 742–745.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
112. Astin JW, Jamieson SM, Eng TC, *et al.*: **An in vivo antilymphatic screen in zebrafish identifies novel inhibitors of mammalian lymphangiogenesis and lymphatic-mediated metastasis.** *Mol Cancer Ther.* 2014; 13(10): 2450–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
113. Gornati D, Zaffaroni N, Villa R, *et al.*: **Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.** *Anticancer Drugs.* 1997; 8(5): 509–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
114. Castellino SM, Friedman HS, Elion GB, *et al.*: **Flunarizine enhancement of**

- mephalan activity against drug-sensitive/resistant rhabdomyosarcoma.** *Br J Cancer.* 1995; **71**(6): 1181–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Silvestrini R, Zaffaroni N, Costa A, *et al.*: **Flunarizine as a modulator of doxorubicin resistance in human colon-adenocarcinoma cells.** *Int J Cancer.* 1993; **55**(4): 636–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 116. Kavanagh BD, Coffey BE, Needham D, *et al.*: **The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment.** *Br J Cancer.* 1993; **67**(4): 734–741.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 117. Sezzi ML, Zupi G, De Luca G, *et al.*: **Effects of a calcium-antagonist (flunarizine) on the *in vitro* growth of B16 mouse melanoma cells.** *Anticancer Res.* 1984; **4**(4–5): 229–34.
[PubMed Abstract](#)
 118. So HS, Kim HJ, Lee JH, *et al.*: **Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin.** *Cell Death Differ.* 2006; **13**(10): 1763–1755.
[PubMed Abstract](#) | [Publisher Full Text](#)
 119. Kang HJ, Yi, Hong YB, *et al.*: **HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction.** *Sci Rep.* 2014; **4**: 7201.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 120. Sakaguchi M, Kuroda Y, Hirose M: **The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor.** *Anesth Analg.* 2006; **102**(4): 1103–1107.
[PubMed Abstract](#) | [Publisher Full Text](#)
 121. Mammoto T, Higashiyama S, Mukai M, *et al.*: **Infiltration anesthetic lidocaine inhibits cancer cell invasion by modulating ectodomain shedding of heparin-binding epidermal growth factor-like growth factor (HB-EGF).** *J Cell Physiol.* 2002; **192**(3): 351–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 122. Baptista-Hon DT, Robertson FM, Robertson GB, *et al.*: **Potent inhibition by ropivacaine of metastatic colon cancer SW620 cell invasion and Na_v1.5 channel function.** *Br J Anaesth.* 2014; **113**(Suppl 1): i39–i48.
[PubMed Abstract](#) | [Publisher Full Text](#)
 123. Piegeler T, Votta-Velis EG, Liu G, *et al.*: **Antimetastatic potential of amide-linked local anesthetics: inhibition of lung adenocarcinoma cell migration and inflammatory Src signaling independent of sodium channel blockade.** *Anesthesiology.* 2012; **117**(3): 548–559.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 124. Poulin H, Bruhova I, Timour Q, *et al.*: **Fluoxetine blocks Na_v1.5 channels via a mechanism similar to that of class 1 antiarrhythmics.** *Mol Pharmacol.* 2014; **86**(4): 378–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 125. Wang Y, Mi J, Lu K, *et al.*: **Comparison of Gating Properties and Use-Dependent Block of Na_v1.5 and Na_v1.7 Channels by Anti-Arrhythmics Mexiletine and Lidocaine.** *PLoS One.* 2015; **10**(6): e0128653.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 126. Mammoto T, Mukai M, Mammoto A, *et al.*: **Intravenous anesthetic, propofol inhibits invasion of cancer cells.** *Cancer Lett.* 2002; **184**(2): 165–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
 127. Besson P, Driffort V, Bon É, *et al.*: **How do voltage-gated sodium channels enhance migration and invasiveness in cancer cells?** *Biochim Biophys Acta.* 2015; pii: S0005-2736(15)00136-4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 128. Brown MT, Herrmann DN, Goldstein M, *et al.*: **Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment.** *J Neurol Sci.* 2014; **345**(1–2): 139–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
 129. Kalman D, Wong B, Horvai AE, *et al.*: **Nerve growth factor acts through cAMP-dependent protein kinase to increase the number of sodium channels in PC12 cells.** *Neuron.* 1990; **4**(3): 355–366.
[PubMed Abstract](#) | [Publisher Full Text](#)
 130. Mnich K, Carleton LA, Kavanagh ET, *et al.*: **Nerve growth factor-mediated inhibition of apoptosis post-caspase activation is due to removal of active caspase-3 in a lysosome-dependent manner.** *Cell Death Dis.* 2014; **5**: e1202.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 131. Chioni AM, Brackenbury WJ, Calhoun JD, *et al.*: **A novel adhesion molecule in human breast cancer cells: voltage-gated Na⁺ channel beta1 subunit.** *Int J Biochem Cell Biol.* 2009; **41**(5): 1216–1227.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 132. Nelson M, Millican-Slater R, Forrest LC, *et al.*: **The sodium channel β1 subunit mediates outgrowth of neurite-like processes on breast cancer cells and promotes tumour growth and metastasis.** *Int J Cancer.* 2014; **135**(10): 2338–2351.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 133. Brisson L, Gillet L, Calaghan S, *et al.*: **Na_v1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H⁺ efflux in caveolae.** *Oncogene.* 2011; **30**(17): 2070–2076.
[PubMed Abstract](#) | [Publisher Full Text](#)
 134. Stettner M, Krämer G, Strauss A, *et al.*: **Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer.** *Eur J Cancer Prev.* 2012; **21**(1): 55–64.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 22 June 2016

<https://doi.org/10.5256/f1000research.7293.r14301>

© 2016 Mutoh M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Michihiro Mutoh

Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Chuo-ku, Japan

This manuscript is well summarized with topics. However, I believe some more information needs to be added.

1. As small molecules, such as FDA approved drugs, affect the tissue of the whole body, the information of the data from genetic findings, such as NaV1.5 knockout mice data, is desired to be included in the text
2. The idea that selecting the voltage gated sodium channel blocker by repurposing of a drug seems attractive to fight invasion and metastasis of cancer. However, a concrete example for the medical use is not shown in the text. Please provide an idea when a patient could use such a drug.
3. Oxidative stress contributes to the invasion process. Figures 3 & 4 show that proton exfusion also plays a role in the invadopodia complex. Do the author has an idea to connect oxidative stress and the voltage gated sodium channel? If not, please ignore this comment.
4. Figure 7: "B1 subunit" should be replaced by "b(symbol)1 subunit".
5. The author describes in the text that the voltage gated sodium channel is overexpressed in cancer tissue, and its blockers could be used as cancer chemoprevention agents. It might be worth writing a review article regarding carcinogenesis and the voltage gated sodium channel blocker in the future.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 19 May 2016

<https://doi.org/10.5256/f1000research.7293.r13165>

© 2016 Waxman S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stephen G. Waxman

Department of Neurology, Yale University, New Haven, CT, USA

This article focuses attention on sodium channels as potential therapeutic targets for metastatic disease. Much work needs to be done to determine whether agents that act on sodium channels will blunt metastatic activity in a clinically meaningful manner, but a spectrum of sodium channel blockers with only minimal side-effects are already used clinically. This novel approach thus merits careful study.

While at first glance it may seem surprising that voltage-gated sodium channels are proposed as molecular targets within (presumably) non-excitable cells, there are many precedents for a role of these channels in controlling effector actions in multiple types of cells that have traditionally been considered non-excitable¹. One example is provided by astrocytes, which express multiple types of sodium channels that are functional within the cell membrane². These astrocytic sodium channels provide a return pathway for Na ions that facilitates operation of the Na-K/ATPase in these cells³. Notably, expression of sodium channels within astrocytes is highly dynamic, a phenomenon that is strikingly seen in scarring astrocytes in disorders such as multiple sclerosis (MS) and its models where expression of Nav1.5 is up-regulated⁴. Recent evidence indicates that these glial sodium channels participate in the astrocytic response to injury, via a cascade that involves Na influx that activates reverse (Ca-importing) Na/Ca exchange⁵. Given the large number of traditionally non-excitable cell-types (including microglia, macrophages, and multiple other cell-types) where expression of voltage-gated sodium channels and a functional role for these channels has been documented (reviewed in Black and Waxman, 2013¹), sodium channels may emerge as therapeutic targets in multiple disorders.

References

1. Black JA, Waxman SG: Noncanonical roles of voltage-gated sodium channels. *Neuron*. 2013; **80** (2): 280-91 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Sontheimer H, Black JA, Ransom BR, Waxman SG: Ion channels in spinal cord astrocytes in vitro. I. Transient expression of high levels of Na⁺ and K⁺ channels. *J Neurophysiol*. 1992; **68** (4): 985-1000 [PubMed Abstract](#)
3. Sontheimer H, Fernandez-Marques E, Ullrich N, Pappas CA, et al.: Astrocyte Na⁺ channels are required for maintenance of Na⁺/K⁺-ATPase activity. *J Neurosci*. 1994; **14** (5 Pt 1): 2464-75 [PubMed Abstract](#)
4. Black JA, Newcombe J, Waxman SG: Astrocytes within multiple sclerosis lesions upregulate sodium channel Nav1.5. *Brain*. 2010; **133** (Pt 3): 835-46 [PubMed Abstract](#) | [Publisher Full Text](#)
5. Pappalardo LW, Samad OA, Black JA, Waxman SG: Voltage-gated sodium channel Nav 1.5 contributes to astrogliosis in an in vitro model of glial injury via reverse Na⁺ /Ca²⁺ exchange. *Glia*. 2014; **62** (7): 1162-75 [PubMed Abstract](#) | [Publisher Full Text](#)

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research